Navigation Links
Hodgkin lymphoma survivors have increased risk of stroke and transient ischemic attack
Date:6/17/2009

Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke, according to a new study published June 17 online in the Journal of the National Cancer Institute.

The study was undertaken because information on clinically verified stroke and transient ischemic attack (TIA), or a "mini stroke," following Hodgkin lymphoma is limited.

In order to quantify the long-term risks, Flora E. van Leeuwen, Ph.D., of the Department of Epidemiology at the Netherlands Cancer Institute in Amsterdam, and colleagues performed a retrospective cohort study among 2,201 Hodgkin lymphoma survivors. The patients, who had survived at least 5 years from the time of diagnosis, had been treated between 1965 and 1995 before age 51. The researchers compared incidence rates of clinically verified stroke and TIA in this cohort with rates in the general population.

After a median follow-up of almost 18 years, 96 patients developed cerebrovascular disease. The incidence rate for stroke was 2.2 times the incidence in the general population. For TIA, it was 3.1. Risks also remained elevated, compared to those in the general population, after prolonged follow-up. Radiation to the neck and mediastinum was associated with increased risk, whereas chemotherapy was not.

"For young survivors of Hodgkin lymphoma, who are at especially increased risk of stroke and TIA, physicians should consider appropriate risk-reducing strategies, such as treatment of hypertension and lifestyle changes to reduce the risk of stroke and TIA," the authors write.

In an accompanying editorial, Dan L. Longo, M.D., of the National Institute on Aging, part of the National Institutes of Health in Bethesda, Md., discusses the study's contribution to the "already overwhelming evidence that radiation therapy in Hodgkin's disease is short-sighted" He applauds the detailed medical documentation and nearly complete follow-up of the patien
'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Radiation May Raise Stroke Risk After Hodgkins
2. Pixantrone Overview in Non-Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
3. Medarex Announces Clinical Data for MDX-1401 in Hodgkins Lymphoma at Annual Meeting of the American Association for Cancer Research
4. New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkins Lymphomas
5. DNA Variations May Alter Risk of Hodgkins Disease
6. DNA differences may influence risk of Hodgkin disease
7. Hodgkins Survivors Prone to Breast Cancer Later
8. Pediatric Hodgkins disease survivors face increased breast cancer risk
9. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
10. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 1Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 2Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 3Mercy Health Plans Receives Five Star Excellent Rating 61479 1Mercy Health Plans Receives Five Star Excellent Rating 61479 2Vibrations key to efficiency of green fluorescent protein 14861 1Vibrations key to efficiency of green fluorescent protein 14861 2Vibrations key to efficiency of green fluorescent protein 14861 3Vibrations key to efficiency of green fluorescent protein 14861 4